MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Bristol-Myers Squibb Co.

Atidarymo kaina

SektoriusSveikatos priežiūra

47.7 -1.59

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

46.95

Max

48.84

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.1B

76M

Pardavimai

442M

12B

P/E

Sektoriaus vid.

14.05

57.333

Pelnas, tenkantis vienai akcijai

1.67

Dividendų pajamingumas

5.04

Pelno marža

0.616

Darbuotojai

34,100

EBITDA

-1.9B

2.6B

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+18.22% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

5.04%

2.63%

Kitas dividendų mokėjimo data

2025-05-01

Kita Ex Dividend data

2025-07-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-21B

100B

Ankstesnė atidarymo kaina

49.29

Ankstesnė uždarymo kaina

47.7

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Bristol-Myers Squibb Co. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-24 11:32; UTC

Uždarbis

Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance

2025-03-11 10:13; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

2025-03-11 10:13; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

2025-04-24 21:24; UTC

Svarbiausios naujienos
Uždarbis

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

2025-04-24 14:15; UTC

Svarbiausios naujienos
Uždarbis

Bristol Myers Squibb Shares Sink Despite Better-than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

2025-04-24 12:37; UTC

Rinkos pokalbiai
Uždarbis

Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk

2025-04-24 11:17; UTC

Uždarbis

Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance

2025-04-24 11:13; UTC

Svarbiausios naujienos
Uždarbis

Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance -- Barrons.com

2025-04-24 10:59; UTC

Uždarbis

Bristol Myers Squibb: Raised 1Q Rev Outlook Reflecting Strong Performance of Growth Portfolio, Better-Than-Expected 1Q Legacy Portfolio Sales and Favorable Impact of About $500M Related to Forex Rates >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol Myers Squibb Latest 1Q Includes Acquired IPRD Charge of $188M >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol Myers Squibb 1Q U.S. Revenue Fell 7% to $7.87B >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol Myers Squibb: Guidance Revisions Include Estimated Impact of Current Tariffs on U.S. Products Shipped to China, but Do Not Account for Any Potential Pharmaceutical Sector Tariffs >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 16% to $5.56B >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Opdivo, Breyanzi, Reblozyl and Camzyos and Reflects Strong Early U.S. Launch of Cobenfy >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol Myers Squibb 1Q Adjusted Gross Margin 73.1% >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol Myers Squibb 1Q International Revenue Fell 2% to $3.33B >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Continued Generic Impact on Revlimid, Pomalyst, Sprycel and Abraxane, as Well as Impact From U.S. Medicare Part D Redesign >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 20% to $5.64B >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol Myers Squibb 1Q Adj EPS $1.80 >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol Myers Squibb Raises 2025 View To Rev $45.8B-$46.8B Vs Prior View $45.5B >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol Myers Squibb 1Q Gross Margin 72.9% >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol Myers Squibb Raises 2025 View To Adj EPS $6.70-Adj EPS $7.00 Vs Prior View $6.55-$6.85 >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol Myers Squibb 1Q Rev $11.2B >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol Myers Squibb 1Q EPS $1.20 >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol-Myers Squibb 1Q Adj EPS $1.80 >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol-Myers Squibb 1Q Rev $11.2B >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol-Myers Squibb 1Q Net $2.46B >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol-Myers Squibb Sees FY Adj EPS $6.70-Adj EPS $7.00 >BMY

2025-04-24 10:59; UTC

Uždarbis

Bristol-Myers Squibb 1Q EPS $1.20 >BMY

2025-03-14 09:30; UTC

Svarbiausios naujienos

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

Akcijų palyginimas

Kainos pokytis

Bristol-Myers Squibb Co. Prognozė

Kainos tikslas

By TipRanks

18.22% į viršų

12 mėnesių prognozė

Vidutinis 57.56 USD  18.22%

Aukščiausias 70 USD

Žemiausias 36 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Bristol-Myers Squibb Co. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

19 ratings

5

Pirkti

13

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

47.54 / 48.82Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Strong Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.